CASI Pharmaceuticals (CASIF) Invested Capital (2020 - 2025)

CASI Pharmaceuticals has reported Invested Capital for 6 years, with the latest figure at -$18.1 million in Q4 2025.

• For the quarter ending Q4 2025, Invested Capital fell 189.41% year-over-year to -$18.1 million; the trailing twelve-month figure through Dec 2025 stood at -$18.1 million (down 189.41% YoY), and the FY2025 full-year result was -$18.1 million, down 189.41% from the prior year.
• Invested Capital for Q4 2025 stood at -$18.1 million, down from $20.2 million in the prior quarter.
• The five-year high for Invested Capital was $9.0 billion in Q2 2024, with the low at -$18.1 million in Q4 2025.
• Historically, Invested Capital has averaged $1.3 billion across 5 years, with a median of $24.2 million in 2023.
• Annual changes were most pronounced in 2021 — Invested Capital increased 3.63% — and 2025, when it plunged 189.41%.
• CASI Pharmaceuticals' Invested Capital stood at $84.5 million in 2021, then slumped by 47.25% to $44.6 million in 2022, then tumbled by 45.79% to $24.2 million in 2023, then fell by 16.26% to $20.2 million in 2024, then slumped by 189.41% to -$18.1 million in 2025.
• The last three Invested Capital figures came in at -$18.1 million (Q4 2025), $20.2 million (Q4 2024), and $9.0 billion (Q2 2024), per Business Quant data.